Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives $120.08 Consensus Price Target from Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $120.0833.

A number of brokerages have recently weighed in on MNPR. Morgan Stanley reiterated an “overweight” rating and set a $130.00 target price on shares of Monopar Therapeutics in a research note on Monday, August 17th. UBS Group set a $125.00 price target on Monopar Therapeutics in a research note on Thursday, July 23rd. HC Wainwright upped their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Finally, BTIG Research increased their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th.

Monopar Therapeutics Price Performance

Shares of MNPR opened at $96.47 on Wednesday. The firm has a market capitalization of $647.31 million, a PE ratio of -44.46 and a beta of 1.49. The company’s 50-day moving average is $111.72 and its 200-day moving average is $80.71. Monopar Therapeutics has a fifty-two week low of $50.07 and a fifty-two week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.02. Analysts predict that Monopar Therapeutics will post -2.94 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34. Following the transaction, the director directly owned 23,751 shares of the company’s stock, valued at approximately $2,654,649.27. This trade represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim Tsuchimoto sold 4,090 shares of Monopar Therapeutics stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the completion of the sale, the director owned 7,396 shares of the company’s stock, valued at $823,840.44. This trade represents a 35.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Siren L.L.C. grew its position in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC increased its stake in Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after acquiring an additional 30,370 shares during the period. Bank of New York Mellon Corp acquired a new position in Monopar Therapeutics in the 2nd quarter valued at $7,124,000. Walleye Capital LLC acquired a new position in Monopar Therapeutics in the 1st quarter valued at $3,458,000. Finally, Bank of America Corp DE raised its holdings in Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after acquiring an additional 53,336 shares in the last quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.